Synthetic Dihexa Angiotensin IV Analog For Neuronal Cell In Vitro Assays
28 Inquiries
1401708-83-5
Pharmaceutical Grade
99%
HONGKONG
mm
5mg/vial,10vials/box
2027-09-26
Tirzepatide,Retatrutide,Semaglutide,GHK-Cu
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Dihexa is a synthetic peptide-based compound and angiotensin IV analog. As a research and pharmaceutical raw material, Dihexa is characterized by its defined molecular structure and peptide properties. It is primarily used for research, analytical testing, compound evaluation, and pharmaceutical development.
Basic Info-
Product Name:
Dihexa
Other Name:L-Isoleucinamide,N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide;Dihexa;N-Hexanoic-Tyr-Ile-(6)aminohexanoic amide
CAS No.:1401708-83-5
Molecular Formula:C27H44N4O5
InChIKeys:InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N
Molecular Weight:504.7
Exact Mass:504.66
Categories:
Characteristics-
Density:
1.111±0.06 g/cm3(Predicted)
Boiling Point:866.2±65.0 °C(Predicted)
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Semaglutide,GHK-Cu
-
Location:
RM 701, UNIT 108, 7/F, TWR B NEW MANDARIN PLAZA 14 SCIENCE MUSEUM RD TSIM SHA TSUI HONG KONG
-
Year of Establishment:
2026
-
-
Inquiry History28 Inquiries
Country Product Purchase Quantity Date Posted
United States
Multi-Product Research Chemical Bulk Sourcing Inquiry
2.6 KG Oct 8, 2026
United States
dihexa
10 MG Sep 28, 2026
Canada
SHLP2 ; PE-22-28; Dihexa ; TAK-653 ; lyophilized
10 PCS Aug 23, 2026
United States
Dihexa
500 G Aug 19, 2026
United States
Dihexa
10 MG Jul 6, 2026
United States
dihexa
10 MG Apr 13, 2026
United States
dihexa
1 G Mar 31, 2026
Canada
Dihexa
1 G Mar 30, 2026
United States
Dihexa
10 MG Mar 23, 2026
United States
DIHEXA
1 KG Mar 23, 2026
United States
dihexa
1 KG Mar 23, 2026
United States
DiHexa
1 KG Mar 17, 2026
United States
Lyophilized DIHEXA
10 MG Feb 18, 2026
United States
Dihexa
2 G Feb 8, 2026
United States
Dihexa
10 MG Jan 21, 2026
United States
Dihexa
10 MG Jan 19, 2026
Belgium
Dihexa
10 G Jan 14, 2026
United States
Dihexa
1 G Dec 14, 2025
United States
Dihexa
100 MG Jul 4, 2025
Bulgaria
Customized peptides high purity Dihexa with fast shipping door to door CAS 1401708-83-5
10 G May 27, 2025 Post an enquiry for this product
More from this Seller
-
-
-
NAD+ NAD Plus Biochemical Coenzyme Raw Powder For In vitro Laboratory Research CAS 53849
Pharmaceutical Grade / 99%
$22/UNIT FOB
-
-
-
-
High Purity SLU-PP-322 (SLU-PP-332) Synthetic ERR Agonist Research Chemical Powder CAS 303760-60-3 for Laboratory Research Only
Pharmaceutical Grade / 99%
$84-85/BOU FOB
-
-
-
-
Tirzepatide LY3298176 White Freeze Dried Powder Laboratory Research Raw Material
Pharmaceutical Grade / 99%
$22/UNIT FOB
-
-
-
-
Synthetic Humanin Peptide For Apoptosis Pathway Laboratory Study Lyophilized Formulation
Pharmaceutical Grade / 99%
-
-
-
-
Mazdutide IBI362 High Purity Synthetic Peptide Raw Material for Laboratory Research
Pharmaceutical Grade / 99%
$153-155/BOU FOB
-
-
-
-
HMG Lyophilized Peptide Powder, High Purity Research Grade Raw Material
Pharmaceutical Grade / 99%
$40-45/BOU FOB
-